Human Papillomavirus (HPV) Self-sampling as a Test of Cure After Treatment of Cervical Intra-epithelial Neoplasia
Human Papillomavirus (HPV) Self-sampling as a Test of Cure After Treatment of Cervical Intra-epithelial Neoplasia
The purpose of this study is to evaluate the performance of HPV self-sampling (self-HPV) in
 detecting residual/recurrent disease in women treated by loop electro-surgical excision
 (LEEP) for CIN1+.
The HPV test is an efficient method to assess the long-term risk of residual/recurrent
 disease in women treated for cervical intraepithelial neoplasia grade 1 or worse (CIN1+).

 Women treated by LEEP for CIN1+ will be invited to participate. Follow-up visits will be
 performed at 6 months and 12 months after treatment and will include cytology, colposcopy
 when indicated and HPV testing. Two weeks before each follow-up visit at the colposcopy
 clinic, a home-based Self-HPV will be organized. A sample of 168 women will be included.
 Agreement between the two methods (Dr-HPV vs. S-HPV) will be measured using the kappa
 statistic (κ).

 the investigators expect to find that Self-HPV may be an accurate method to predict residual
 and recurrent disease in women previously treated by LEEP.
Inclusion Criteria:

 -  attending colposcopy clinic

 -  biopsy-proven CIN1+ lesion

 -  understands study procedures and accepts voluntarily to participate by signing the
 informed consent form

 Exclusion Criteria:

 -  pregnancy